A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.
Manegold, C van Zandwijk, N Szczesna, A Zatloukal, P Au, J Blasinska-Morawiec, M Serwatowski, P Krzakowski, M Jassem, J Tan, E
Manegold, C
van Zandwijk, N
Szczesna, A
Zatloukal, P
Au, J
Blasinska-Morawiec, M
Serwatowski, P
Krzakowski, M
Jassem, J
Tan, E
Citations
Altmetric:
Abstract
This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC).
Description
Date
2012-01
Publisher
Collections
Keywords
Type
Article
Citation
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. 2012, 23 (1):72-7 Ann Oncol